SALT
LAKE CITY, July 2, 2024 /PRNewswire/ --
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or
"Co-Dx™"), a molecular diagnostics company with a unique, patented
platform for the development of molecular diagnostic tests,
announced today that use of the Company's vector control technology
will expand to the 15th U.S. state following an
installation in Nevada next
week.
Co-Dx vector control technology includes Vector Smart® PCR tests
used in environmental (non-diagnostic) surveillance of mosquito
pools for mosquito-borne illnesses like West Nile virus, Zika,
dengue and chikungunya. Mosquito abatement districts (MADs) and
other vector control customers can use Vector Smart tests as well
as other equipment sold and installed by Co-Diagnostics to receive
same-day results of mosquito pool testing, allowing for quicker and
more efficient prevention of disease transmission to humans and
animals.
Dwight Egan, Co-Diagnostics CEO,
remarked, "We are pleased with the continued growth of our vector
control platform and products. The importance of providing
front-line surveillance against the spread of these mosquito-borne
pathogens is increasing, as many experts believe that climate
change is driving an expansion of mosquitos capable of carrying
deadly illnesses to more areas.
"The broader vector control industry extends beyond mosquito
surveillance to other vectors, including birds and livestock.
Providing industry-leading PCR tests and equipment can support
vector control activities to keep our communities safe from
infectious diseases, and aligns with our mission of leveraging our
technology platform to improve the quality of life on a global
scale."
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets
state-of-the-art diagnostics technologies. The Company's
technologies are utilized for tests that are designed using the
detection and/or analysis of nucleic acid molecules (DNA or RNA).
The Company also uses its proprietary technology to design specific
tests for its Co-Dx PCR at-home and point-of-care platform and to
locate genetic markers for use in applications other than
infectious disease.
Forward-Looking Statements:
Statements in this
release that are not historical are forward-looking statements made
pursuant to the safe harbor provisions of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
statements can be identified by words such as "believes,"
"expects," "estimates," "intends," "may," "plans," "will" and
similar expressions, or the negative of these words.
Forward-looking statements include statements made with respect to
the use of Vector Smart tests and other equipment will allow for
quicker and more efficient prevention of disease transmission to
humans and animals and that climate change is driving an expansion
of mosquitos capable of carrying deadly illnesses to more areas.
Such forward-looking statements are based on facts and conditions
as they exist at the time such statements are made and predictions
as to future facts and conditions. Forward-looking statements are
subject to inherent uncertainties, risks and changes in
circumstances. Actual results may differ materially from those
contemplated or anticipated by such forward-looking statements.
Readers of this press release are cautioned not to place undue
reliance on any forward-looking statements. There can be no
assurance that any of the anticipated results will occur on a
timely basis or at all due to certain risks and uncertainties, a
discussion of which can be found in our Risk Factors disclosure in
our Annual Report on Form 10-K, filed with the Securities and
Exchange Commission (SEC) on March 14,
2024, and in our other filings with the SEC. The Company
does not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities
laws.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-expands-vector-control-customer-base-to-25-customers-across-15-us-states-302188033.html
SOURCE Co-Diagnostics